S U M M A R Y B A C K G R O U N D :
The tuberculin skin test (TST) is used to help diagnose tuberculosis (TB) in acutely ill hospitalised children. O B J E C T I V E : To investigate the potential augmentative effect of topical calcipotriol (a vitamin D analogue) or zinc on TST induration.
M E T H O D S :
Three TSTs were performed among 64 hospitalised children; each site was covered with topical aqueous cream (control), calcipotriol or zinc and assessed 24 and 48 h later by investigators blinded to all topical applications. R E S U LT S : TSTs were reactive in 15 (23.4%) children, of whom 13 (20.3%) were TST-positive. Topical calcipotriol and zinc induced TST positivity in two children with reactive but negative control TSTs. These treatments, however, did not significantly increase TST positivity rates. In children with reactive TSTs, the median 48 h induration diameter was not significantly different between the control, calcipotriol-or zinc-treated groups, which were respectively 12.0 (25%-75% IQR 5.0 -18.0), 14 .0 (25%-75% IQR 10.0 -15.0) and 12.0 (25%-75% IQR 8.0 -15.0) mm. Topical treatments did not induce TST reactivity or TST positivity in children with cultureconfirmed TB disease (n ¼ 4), human immunodeficiency virus infection (n ¼ 18) or kwashiorkor (n ¼ 9). C O N C L U S I O N S : Topical calcipotriol or zinc does not induce TST reactivity or significantly increase TST positivity rates in acutely ill hospitalised children. However, further studies are required to assess the effects of topical treatments on TST positivity in severely malnourished children. K E Y W O R D S : vitamin D; Mantoux; HIV; malnutrition THE TUBERCULIN SKIN TEST (TST), together with suggestive clinical and chest radiological signs, is commonly used to diagnose Mycobacterium tuberculosis disease in acutely ill hospitalised children admitted to health facilities in sub-Saharan Africa, a region burdened by the twin epidemics of the human immunodeficiency virus (HIV) and tuberculosis (TB). 1 The TST, however, is often non-reactive in malnourished and immune-suppressed children with M. tuberculosis infection.
The application of topical treatments may induce or increase TST induration, as is the case with candida skin test reactivity. 2 The application of topical zinc sulphate enhances TST reactivity in elderly subjects, 3 healthy adults at high risk of TB, 4 and, according to a preliminary report, in Peruvian children suspected of having M. tuberculosis infection or disease. 5 As yet, there are no data on the effect of topical zinc on TST reactivity in individuals living in sub-Saharan Africa.
In addition, we hypothesised that calcipotriol, a topical analogue of 1,25 dihydroxyvitamin D 3 (1,25- [OH] 2 -D3) used in the treatment of psoriasis, 6 affects TST reactivity. Vitamin D deficiency is associated with reduced in vivo TST reactivity in experimental TB, 7 and vitamin D supplementation restores TST responses in elderly subjects who are vitamin D deficient. 8 Experimentally, 1,25-(OH) 2 -D 3 induces the production of cathelicidin, a peptide with antimycobacterial properties. [9] [10] [11] We therefore investigated the effects of topical calcipotriol and zinc on TST reactivity in children hospitalised with suspected TB.
MATERIALS AND METHODS

Patients
Children admitted to the general paediatric wards at the Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa, from March 2009 to September 2012 were eligible for enrolment if they were being investigated for tuberculous infection. Although this is one of the larger departments in Southern Africa, the setting is typical of most public health facilities in the region. Most children admitted to the hospital are aged ,5 years and about 20% of admitted children are HIV-infected. 12 Study inclusion criteria included age 6 weeks to 14 years, a radiologically confirmed diagnosis of pneumonia or a clinical suspicion of extra-pulmonary TB, and obtaining the care giver's informed consent. Children were excluded if they were receiving anti-tuberculosis treatment, if a TST had previously been performed or if pre-existing illnesses prevented the application of calcipotriol ointment. Convenience sampling, based on the availability of the study investigators to read the TST at 24 and 48 h, was used to enrol eligible patients. HIV infection was confirmed using DNA polymerase chain reaction in children aged ,18 months and by using enzyme-linked immunosorbent assays in older children. Gastric aspirates and TST are performed in children suspected of having M. tuberculosis infection. A diagnosis of TB disease, rather than latent tuberculous infection (LTBI), is considered in clinically symptomatic children aged 5 years who are TST-positive; these children are routinely given anti-tuberculosis treatment because of the high risk of progression from untreated LTBI to disseminated TB. 13 The Human Research Ethics Committee of the University of the Witwatersrand, Johannesburg, South Africa, approved the study (clearance number M080619).
Topical applications
Zinc sulphate crystals were dissolved in sterile water, then blended into aqueous cream creating a zinc cream containing 2% elemental zinc. Calcipotriol (50 lg/g or 0.005%) was obtained from a commercial supplier (Donovex Cream, Adcock Ingram Limited, Bryanston, South Africa). Aqueous cream was applied over the control TST site. The study was modified after the first 25 children were enrolled, primarily because of concerns about the safety of the topical zinc sulphate cream. Study investigator SGL, who administered the TSTs and applied the topical dressings, noted that a small superficial skin ulcer, about 1-2 mm in diameter, occurred on zinc sulphate cream-covered tests only, even in children with nonreactive TSTs. The ulcer coincided with the site where the TST syringe needle pierced the skin and not over the skin directly overlying the intradermally injected tuberculin solution; the ulcer could be easily distinguished from an indurated TST and did not influence tuberculin measurements. A second batch of zinc cream, made by a different pharmacist using sonication and homogenisation to blend the zinc sulphate solution into the aqueous cream, produced the same effect on a further six patients. The study was interrupted until a commercially prepared 15% zinc oxide ointment containing 12% elemental zinc (Adminicle Trading, Edenvale, South Africa), which produced no similar ulceration, became available.
Tuberculin skin test administration and reading Three separate doses of 0.1 ml RT23 (Statens Serum Institute, Copenhagen, Denmark) containing 2 tuberculin units were injected intradermally (Mantoux method) into the volar surfaces of the right and left forearms of 64 children. Two TSTs were administered in one forearm and one in the other forearm. The skin was anaesthetised by a topical application of EMLA cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) at least 60 min before administering TST. All TSTs were performed by SGL using an insulin syringe and needle. A discreet wheal measuring .6 mm in diameter (usually around 9-10 mm in diameter) was evident immediately after the administration of all TSTs, and no TST needed re-injection at another site. The skin surrounding the TST was marked using a black felt-tip marker. Thereafter, each TST was immediately covered with a topical application of aqueous cream, zinc or calcipotriol in a random manner and their placement was recorded. The topical treatments were secured using transparent occlusive dressings. All other study investigators were blinded to the treatments. The TSTs were read by investigators within a 90-min period, 24 and 48 h after TST administration. The TSTs, which can be read after 48 -72 h, 14 were definitively read 48 h after administration for convenience.
TSTs were initially categorised as reactive or nonreactive by two groups, each comprising the same two investigators: the first group assessed the first 39 enrolled children and the second group assessed the next 25 enrolled children. Reactive TSTs were categorised as positive or negative. The following study definitions were used: 1 Tuberculin reactivity: any skin induration detected by palpation and/or Sokal's 'medium ball-point' method. Transverse diameters of reactive TSTs were measured using the Sokal method 15 2 TST positivity: skin induration !10 mm (or !5 mm for HIV-infected or severely malnourished children) 16 ,17 3 TST negativity: skin induration ,10 mm (or ,5 mm for HIV-infected or severely malnourished children).
The transverse diameter of the indurations was measured to the nearest millimetre using Sokal's method after removal of occlusive dressings and topical applications.
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Statistics
Anthropometric Z-scores were calculated using the World Health Organization (WHO) Anthro and AnthroPlus software programmes (Department of Nutrition, WHO, Geneva, Switzerland). The median anthropometric Z-scores were compared in children with and without positive TSTs using Mann-Whitney tests. The inter-observer agreement for TST reactivity was determined using the kappa (j) statistic. The effect of topical calcipotriol and zinc on TST positivity (defined above) was assessed using a v 2 analysis of 2x3 contingency tables. Patient-matched measurements of 48 h positive TSTs were compared using the Kruskal-Wallis test. Statistical analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com).
Sample size calculation
Based on previous reports showing that topical zinc increases TST reactivity by 32% 4 and TST positivity by 38%, 3 we designed our study to detect a 20% increase in TST positivity rates. A preliminary analysis of 64 patients indicated that our study had 85% power (a ¼ 0.05; two-tailed) to detect a 20% difference in TST positivity rates for both control vs. calcipotriol and control vs. topical zinc groups.
RESULTS
Demographic characteristics
The median age of the 64 children enrolled was 22 months (interquartile range [IQR] 11 -49 months); there was no difference in the median ages of the TSTpositive and TST-negative children (P ¼ 0.9503) ( Table 1) . Thirty-two (50%) children were male and 18 (28.1%) were HIV-infected. M. tuberculosis was cultured from four children (6.3%) and non-tuberculous mycobacteria (NTM) were cultured from another four (6.3%). Two enrolled children died: one was HIV-infected, but both had culture-confirmed M. tuberculosis disease. Malnutrition was common: 41.4% of the children were underweight for age, 47.1% were stunted and 23.5% had wasting. Nine children were diagnosed with kwashiorkor and three with marasmus (Table 1) .
HIV-infected children were less likely to be TSTpositive (P ¼ 0.026). No TST reactivity was noted in any of the control, calcipotriol or zinc TSTs in any HIV-infected child (n ¼ 18, including five children who also had kwashiorkor [n ¼ 3] or marasmus [n ¼ 2]). No TST reactivity was noted in non-HIV-infected children with kwashiorkor (n ¼ 6) or marasmus (n ¼ 1), children with culture-confirmed M. tuberculosis disease (n ¼ 4) or in children from whom NTM were isolated (n ¼ 4). The anthropometric characteristics are shown in Table 2 . Effect of calcipotriol ointment and topical zinc cream on tuberculin reactivity TSTs were reactive in 15 (23.4%) children, of whom 13 (20.3%) were TST-positive. Topical calcipotriol and zinc induced TST positivity in two children with reactive but negative control TSTs. These treatments, however, but did not induce an induration in those 49 children with non-indurated (i.e., non-reactive) control TSTs (Figure 1 ). Neither topical calcipotriol nor zinc significantly affected the number of positive TSTs: after 48 h, control and zinc-covered TSTs were positive in 11 (17.2%) children, whereas calcipotriolcovered TSTs were positive in 13 (20.3%) (Figure 2) . In reactive TSTs, the median induration size at 48 h was 12.0 mm (25% -75% IQR 5.0 -18.0) for the control group, 14.0 (25% -75% IQR 10.0 -15.0) for the calcipotriol group and 12.0 (25% -75% IQR Table 1 Demographic data of TST-positive and -negative children* 8.0 -15.0) for the zinc group. These induration sizes were not significantly different in the three groups (P ¼ 0.735; Figure 3 ).
Tuberculin skin test characteristics
There was very good inter-observer reliability for the presence of TST induration as a binary measure: the j statistic was 0.All children (n ¼ 64) n (%) TST-positive (n ¼ 11) n (%) TST-negative (n ¼ 53) † n (%) P
DISCUSSION
Topical calcipotriol or zinc did not enhance TST reactivity or significantly increase TST positivity rates in hospitalised children investigated for TB in a high TB-HIV disease burden setting, in contrast to previous studies, [3] [4] [5] which reported that topical zinc enhances TST reactivity. Specifically, the topical treatments did not assist in the diagnosis of TB in malnourished and/or HIV-infected children, including four children in whom TB was subsequently proven (i.e., culture-confirmed TB disease). Our failure to measure baseline serum zinc or 25 hydroxyvitamin D levels before enrolment is a major limitation; however, the ineffectiveness of topical calcipotriol or zinc on TST positivity is probably not due to the confounding effect of oral zinc or vitamin D supplementation. No child with a reactive TST in this study received oral vitamin D supplementation. Oral zinc sulphate was prescribed for nine children with kwashiorkor and four other children with lower respiratory tract infection and co-existing gastroenteritis; none of these children had reactive TSTs. Topical calcipotriol and zinc-induced TST positivity in two children with severe wasting (weight-forheight Z-score ,-3). However, the control TST was reactive, but not quite positive (i.e., 4 mm) in one child and reactive at 24 h but not at 48 h in the other child. Furthermore, topical calcipotriol or zinc did not induce any TST reactivity in the vast majority of severely malnourished children with non-reactive control TSTs.
Although hypersensitivity responses are suppressed in skin pre-treated with topical vitamin D analogues, 18 we did not observe a suppressive effect of topical calcipotriol on TST reactivity when calcipotriol was Effect of topical calcipotriol and zinc on TST applied to TSTs. We speculate that this is explained by the lack of suppression of epidermal antigen-presenting cell activity by calcipotriol. 19 We further speculate that the children in this study either did not have low zinc levels or that other biological mechanisms drive TST anergy, although topical zinc improves zinc levels in acutely ill, hospitalised children. Zinc oxide may exert a 'weaker' biological effect in contrast to zinc sulphate. Golden et al. reported that zinc oxide is 'virtually insoluble' through the skin, 2 but this may not be true: topical zinc oxide is thought to maintain serum zinc levels in patients receiving total parenteral nutrition, 20 and topical zinc oxide increases epidermal zinc levels in humans. 21 Our study has other limitations. Although our sample size may have resulted in the failure to detect smaller, but statistically significant, changes in TST induration size, we decided that an improvement of TST positivity rates by 20% is likely to influence clinical practice. If we assume that our result, which shows a small, non-significant increase in TST positivity rate, is valid, then one additional TST will be positive for every 32 children who receive topical calcipotriol; there were no additional TST-positive tests in the children treated with topical zinc.
In our study, zinc sulphate cream containing a final concentration of 2% elemental zinc induced a small superficial ulcer over the site where the syringe-needle breached the skin, distal to the site of intradermal tuberculin deposition. This superficial ulcer resolved spontaneously without sequelae. We speculate that the presence of undissolved zinc particles in the cream may precipitate a local reaction at the site of the broken skin. However, a second batch of zinc sulphate solution mixed into the aqueous cream carrier using a homogeniser and sonication produced similar results. Alternatively, the ulceration may be due to the higher concentration of zinc sulphate used in this study: local skin effects such as inflammation, swelling and necrosis are described in adults treated with topical zinc sulphate for the therapy of melasma, 22 herpes genitalis 23 and cutaneous leishmaniasis. 24 Despite the widespread use of topical zinc treatments to treat various dermatological conditions in children, safety and efficacy studies are lacking; 25 topical calcipotriol is used to treat psoriasis and is well tolerated, but may cause local irritation. 26 In this study, topical treatments were used in doses much smaller than the recommended therapeutic doses.
Anergic cellular immune responses are most likely to have accounted for the non-reactive TSTs seen in the majority of our study children who had routinely received bacille Calmette-Guérin vaccination at birth. Although we did not use a concomitant control antigen such as Candida albicans (which is not available in South Africa), the failure of TST reactivity in children with culture-confirmed M. tuberculosis disease suggests that anergic response, rather than non-exposure to mycobacteria, is the main reason for TST non-reactivity in hospitalised children. Two of four children with culture-confirmed M. tuberculosis disease were HIV-infected, and we speculate that coexisting severe acute malnutrition (specifically kwashiorkor) and HIV infection contributed to the anergic TST responses in the four children with cultureconfirmed M. tuberculosis disease.
To control for the potential lack of immunogenic potency of RT23 in a clinical setting, we used unopened, sealed vials of RT23 taken from the same box. As most children were recruited in groups, the same bottle of RT23 was used to administer TSTs to groups of 2-4 children. As 12/14 (85.7%) children with reactive TSTs were given RT23 in this way, we do not believe that the high rates of TST non-reactivity in the other children were due to inert preparations of RT23.
CONCLUSION
Our preliminary study suggests that topical calcipotriol and zinc do not augment TST responses in acutely ill, hospitalised children. We suggest that further studies should focus on children with severe acute malnutrition who routinely receive standard micronutrient supplementation (which includes zinc, but not vitamin D): significant changes in TST positivity rates, especially if correlated with baseline zinc and vitamin D measurements, will confirm or refute the usefulness of topical treatments on TST positivity in severely malnourished children. (20,3%) . El calcipotriol y el cinc tópicos indujeron la positividad de la prueba en dos niños con prueba reactiva pero negativa en el punto de referencia. Sin embargo, estos tratamientos no aumentaron de manera significativa las tasas de positividad de la reacción TST. En los niños con TST reactiva, la mediana del diá metro de la induración a las 48 h no fue significativamente diferente entre el grupo testigo (12,0 mm; IQR 25%-75% 5,0-18,0) y los grupos tratados con calcipotriol (14,0 mm; IQR 25%-75% 10,0-15,0) o cinc (12,0 mm; IQR 25%-75% 8,0-15,0). Los tratamientos tópicos no indujeron la reactividad ni la positividad de la TST en los niños con enfermedad tuberculosa confirmada por cultivo (n ¼ 4), infección por el virus de la inmunodeficiencia humana (n ¼ 18) ni kwashiorkor (n ¼ 9). C O N C L U S I Ó N : La aplicación tópica de calcipotriol o cinc no induce reactividad de la TST ni un aumento significativo de las tasas de positividad a la misma en los niños gravemente enfermos y hospitalizados, pero se precisan nuevos estudios que evalúen los efectos de los tratamientos tópicos en la positividad de la reacción a la TST en niños con desnutrición grave.
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